Friday, December 5, 2025

NIH Solicitation: Business Development consultants for the National Institute on Drug Abuse (NIDA)

Solicitation: 75N95020Q00024

The purpose of this requirement is to procure services of business development consultants to provide business development recommendations to the NIDA Step Up for Substance Use Disorder (SUD) program.

The role of the business development consultants may include but is not limited to the following responsibilities and tasks:

  • Source and generate business plans which include milestones and clear exit strategies from application pool (drug candidates) by evaluating the commercial, regulatory, and development feasibility.
  • Perform target due diligence and competitor analysis using public and private drug development databases such as Citeline Pipeline, Thomson Reuters’ Integrity, FDA Orange Book, USPTO, and Clinical Trials.gov.
  • As the exit strategy for projects coming out of the NIDA’s Step Up for Substance Use Disorder program, identify and assist in establishing the collaboration with investors who may become the collaborators, investors or the business partners of the successful projects.
  • Help to identify Contract Research Organizations (CROs) for the applicants which may be required for future work on the NIDA’s Step Up for Substance Use Disorder program…

Read more here.

[related-post]

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Innovation in Action: Advancing Government Health with Philips

FORUM is proud to partner with Philips for a series of articles on their groundbreaking innovations in health technology that serve public- and private sector citizens and service members. Please take a look to learn more about how Philips is advancing modern and efficient health care, while improving lives for generations to come.

Don’t Miss A Thing

Jackie Gilbert
Jackie Gilbert
Jackie Gilbert is a Content Analyst for FedHealthIT and Author of 'Anything but COVID-19' on the Daily Take Newsletter for G2Xchange Health and FedCiv.

Subscribe to our mailing list

* indicates required